e l f Beauty Inc vs Johnson & Johnson — how do they compare? e l f Beauty Inc trades at $74.47 (market cap $4.37B), while Johnson & Johnson trades at $250.26 (market cap $594.63B). The key difference: Johnson & Johnson is far larger — about 136.1× e l f Beauty Inc's market cap, and Johnson & Johnson pays a 2.17% dividend while e l f Beauty Inc pays none. Which is the better fit depends on your goals.
| ELF | JNJ | |
|---|---|---|
Market Cap | $4.37B | $594.63B |
Sector | Technology | Health |
52-Week High | $146.67 | $267.24 |
52-Week Low | $49.57 | $162.98 |
Enterprise Value | $5.00B | $627.57B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.17% |
Signals from Pluang's Aura AI — not financial advice
ELF Beauty trades at $74.77, up 3.49% with a bullish technical signal supported by moving averages. The company shows strong revenue growth reaching $1.31B in 2025 but faces margin compression with net income margin at 1.61%. Recent earnings beats and analyst coverage skewed toward buy/hold suggest cautious optimism. Technical indicators show support at $73 and resistance at $76, with RSI neutral but ADX signaling strong trend momentum.
Outlook remains mixed: growth initiatives in skincare and international markets provide upside, but high P/E of 168.68 and margin pressures pose valuation risks. Analyst consensus target of $74.42 aligns with current price, indicating limited near-term upside. Key risks include competitive pressures and execution on brand expansion.
Johnson & Johnson (JNJ) trades at $249.42, down 1.75% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of $2.90, beating estimates, and raised full-year guidance. Revenue grew 6.6% annually, supported by strong pharmaceutical sales. Analyst consensus is bullish with a $281 price target, and the stock offers a stable dividend with recent payouts of $1.34 per share.
Outlook remains positive due to robust fundamentals, innovation in medtech and pharmaceuticals, and dividend king status. Risks include patent expirations, regulatory pressures, and macroeconomic volatility. The current valuation at P/E 28.66 may limit near-term upside, but long-term growth prospects appear solid.
Trailing returns across standard periods
Latest headlines on both assets
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →